Nilotinib

製品コードS1033 バッチS103311

印刷

化学情報

Chemical Structure Synonyms AMN-107 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C28H22F3N7O
分子量 529.52 CAS No. 641571-10-0
Solubility (25°C)* 体外 DMSO 13 mg/mL (24.55 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
4%DMSO 30%PEG300 5%Tween80 61%ddH2O

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

 3.000mg/ml (5.67mM) Taking the 1 mL working solution as an example, add 40 μL of 75 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 610 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Nilotinib is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.
in vitro Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. This compound induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. It also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, this chemical not only inhibits activation of PDGFR, but also TGFRII through Src. It significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by this agent. [2] This inhibitor suppresses most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] It inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. This compound is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] It also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). This treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] It inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]
in vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. This compound could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] It attenuates the extent of lung injury and fibrosis. This therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] This chemical prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]
特徴 A selective inhibitor of native and mutant Bcr-Abl.

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Human primary Schwann and schwannoma cells
濃度 1-10 μM
反応時間 72 hours
実験の流れ Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of this compound is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
動物実験 動物モデル Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
投薬量 75 mg/kg, 100 mg/kg
投与方法 Oral administration

参考

  • https://pubmed.ncbi.nlm.nih.gov/17068153/
  • https://pubmed.ncbi.nlm.nih.gov/21251937/
  • https://pubmed.ncbi.nlm.nih.gov/21220945/
  • https://pubmed.ncbi.nlm.nih.gov/21727212/
  • https://pubmed.ncbi.nlm.nih.gov/21659722/
  • https://pubmed.ncbi.nlm.nih.gov/15710326/

カスタマーフィードバック

Data from [Molecules, 2014, 19, 3356-75]

Data from [Urol Oncol, 2014, 0.1016/j.urolonc.2014.06.001]

Data from [Urol Oncol, 2014, 0.1016/j.urolonc.2014.06.001]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Nilotinib attenuates vascular pathology in experimental cerebral malaria [ Blood Adv, 2025, bloodadvances.2024015364] PubMed: 39993234
CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells [ Cell Death Discov, 2025, 11(1):62] PubMed: 39955308
Nbeal2 Inactivation Triggers Abl1 Stabilisation and Dysregulated Subcellular Localisation of the Multi-Drug-Resistant Protein MDR1 (ABCB1) in Mast Cells [ Immunology, 2025, NONE] PubMed: 41111259
Electrochemical assay for the quantification of anticancer drugs and their inhibition mechanism [ Methods, 2025, 241:13-23] PubMed: 40345605
Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation [ Toxicol Lett, 2025, 406:31-37] PubMed: 39988211
Structural Identification of Major Molecular Determinants for Phosphotyrosine Recognition in Tyrosine Kinases Reveals Tumour Promoting and Suppressive Functions [ bioRxiv, 2025, 2025.06.10.658871] PubMed: 40661594
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease [ Nat Commun, 2024, 15(1):651] PubMed: 38246924
Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation [ Nat Commun, 2024, 15(1):2089] PubMed: 38453961
The molecular basis of Abelson kinase regulation by its αI-helix [ Elife, 2024, 12RP92324] PubMed: 38588001
Satellite cell-derived TRIM28 is pivotal for mechanical load- and injury-induced myogenesis [ EMBO Rep, 2024, 10.1038/s44319-024-00227-1] PubMed: 39143258

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。